InvestorsHub Logo
Followers 61
Posts 1493
Boards Moderated 0
Alias Born 01/31/2014

Re: antihama post# 678651

Friday, 03/15/2024 1:16:54 PM

Friday, March 15, 2024 1:16:54 PM

Post# of 694211
ATLnsider found this previously. The DCVax-L MAA filed is for approval in all malignant gliomas.
https://asgct.org/global/documents/asgct-citeline-q4-2023-report.aspx?_zs=gxXTc&_zl=aQMt3
(on page 14)

Drug: DCVax-L
Event Type: Filing for Approval (UK)
Indication: Brain Cancer - malignant glioma; AA and glioblastoma (GBM)
Molecule: Cellular
Event Date: 21 December 2023
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News